<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204451</url>
  </required_header>
  <id_info>
    <org_study_id>Bio 05-67</org_study_id>
    <secondary_id>CIHR MOP 11489</secondary_id>
    <nct_id>NCT00204451</nct_id>
  </id_info>
  <brief_title>Human Ovarian Follicular Dynamics and Emergency Contraception</brief_title>
  <official_title>Human Ovarian Follicular Dynamics and Emergency Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <brief_summary>
    <textblock>
      The researchers hypothesize that emergency contraception (EC) will initiate the changes&#xD;
      associated with atresia or ovulatory failure at all stages of follicular development and that&#xD;
      the image attributes associated with atresia will be similar regardless of the diameter of&#xD;
      the dominant follicle when ovarian suppression is initiated. Second, changes associated with&#xD;
      atresia may be observed, but ovulation of the dominant follicle is unimpeded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center, randomized, open-label, double-controlled protocol to study&#xD;
      the pattern of ovarian follicular growth and regression in two groups of women. The first&#xD;
      group will use Plan B, which is a progesterone only OC containing 0.75 levonorgestrel. The&#xD;
      second group of women will use the Yuzpe regimen, which uses 50 mg ethinyl estradiol/0.5 mg&#xD;
      levonorgestrel pills at different stages of the menstrual follicular cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>follicle development</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>ovulation status</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>peripheral blood pressure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial development</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Contraception</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.75 levonorgestrel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg ethinyl estradiol/0.5 mg levonorgestrel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female volunteers of childbearing potential;&#xD;
&#xD;
          2. Are first time users of oral contraception (OC) or have discontinued OC at least 1&#xD;
             month prior to study entry;&#xD;
&#xD;
          3. Age between 18 and 40 years old;&#xD;
&#xD;
          4. Normal body mass index (18-38);&#xD;
&#xD;
          5. Has signed informed consent form; and&#xD;
&#xD;
          6. Is in good health as confirmed by medical history, physical examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A positive pregnancy test will automatically exclude the volunteer from participation&#xD;
             in this study.&#xD;
&#xD;
          2. Any contraindication for oral contraception use;&#xD;
&#xD;
          3. Irregular menstrual cycles;&#xD;
&#xD;
          4. Ultrasonographic evidence of ovarian dysfunction, such as polycystic ovary syndrome&#xD;
             (PCOS);&#xD;
&#xD;
          5. Pregnancy (suspected or diagnosed) or lactation;&#xD;
&#xD;
          6. History or suspicion of drug or alcohol abuse;&#xD;
&#xD;
          7. Participation in an investigational drug trial within the 30 days prior to selection;&#xD;
&#xD;
          8. Exhibits a disorder that is a contraindication to steroid hormonal therapy, including,&#xD;
             for example, the following conditions:&#xD;
&#xD;
               -  history of, or actual, thrombophlebitis or thromboembolic disorders.&#xD;
&#xD;
               -  history of, or actual, cerebrovascular disorders.&#xD;
&#xD;
               -  history of, or actual, myocardial infarction or coronary artery disease.&#xD;
&#xD;
               -  acute liver disease.&#xD;
&#xD;
               -  history of, or actual, benign or malignant liver tumors.&#xD;
&#xD;
               -  history of, or suspected, carcinoma of the breast.&#xD;
&#xD;
               -  known, or suspected, estrogen-dependent neoplasia.&#xD;
&#xD;
               -  undiagnosed abnormal vaginal bleeding.&#xD;
&#xD;
               -  any ocular lesion arising from ophthalmic vascular disease, such as partial or&#xD;
                  complete loss of vision or defect in visual field.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger A Pierson, MS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salma T Hanna, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olufemi A Olatunbosun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ob-Gyn Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril. 2003 Jul;80(1):34-42.</citation>
    <PMID>12849799</PMID>
  </reference>
  <reference>
    <citation>Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003 Jul;80(1):116-22.</citation>
    <PMID>12849812</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Roger Pierson</investigator_full_name>
    <investigator_title>Ph.D., FEAS, FCAHS, MS</investigator_title>
  </responsible_party>
  <keyword>emergency contraception</keyword>
  <keyword>follicle</keyword>
  <keyword>ovulation</keyword>
  <keyword>blood pressure</keyword>
  <keyword>Fertility Control</keyword>
  <keyword>Inhibition of fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

